Cardiol Therapeutics Inc.
- CRDL
- NASDAQ
- Drug Manufacturers - Specialty & Generic
- Cardiovascular Therapies
- Anti-inflammatory/Fibrosis Drugs
$1.10
Quote Oct 19, 2026, 08:00 PM UTC
−41.49%over the last month
Max drawdown −41.8%From 1-month high −41.8%3 months −11.3%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Cardiol Therapeutics
Cardiol Therapeutics Inc. is a clinical-stage life sciences firm dedicated to discovering and advancing anti-fibrotic and anti-inflammatory therapies for cardiovascular disease (CVD). Its leading candidate, CardiolRx, is currently undergoing a multi-national, randomized, double-blind, placebo-controlled Phase II/III study.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Exchange
NASDAQ
Employees
18
Market value
$110.3M
Quote Oct 19
Analyst target
$8.00
+627.3% from here
Floor
$1.05
4.5% below price
Resistance
$1.10
0.1% above price
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about CRDLPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free